| ObjectivesThe purpose of this study was to evaluate the effect of clinical pathway (CP) for breast hyperplastic disease, provide evidence for revamp clinical pathway, improve the quality of clinical medicine, and provide evidence for establishing and popularizing Chinese clinical medicine programs.MethodsThe CP form was designed base on the previous program about Chinese medical treatment of the breast hyperplasia disease. Using non randomized control method,120 outpatients who were diagnosed as breast hyperplasia disease from Guangdong Provincial Hospital of TCM were divided into 2 groups, clinical pathway group(2009.2-2009.10) and the control group(2009.11-2010.4). Each group has 60 cases. With the curative effect, cost, patient satisfaction, waiting time and the CP variation, using the descriptive and deductive statistical analysis to evaluate the effect of clinical pathway.ResultCompared with the CP group and the control group, the total and different syndromes curative effect, and the main symptoms (breast pain, breast lump distribution, hardness and size, accompany symptoms) had no statistic difference. For heavier breast tenderness, after treatment, the score of the CP group was lower than the control group (P< 0.05). Compared with the control group, the total cost and mean cost per day of CP group were reduced obviously (P<0.01), the average waiting time of CP group was reduced 45.25 minutes. On patient satisfaction, every items of CP group was increased. Difference had statistically significant (P< 0.01).2 cases (3.33%) in CP group were dropout pathway, because of without come back to see the doctor after a month treatment. And 25 cases (41%) had variations. All of the reasons were patient factors.ConclusionWith the steady medical quality, the clinical Chinese medical treatment pathway for breast hyperplastic disease can reduce medical cost and outpatient waiting time, improve patient satisfaction, standardizing medical process. It should be widely applied. |
PDF Full Text Request